Improved Treatment through Improved Technology

RenBio’s MYO antibody delivery system is compatible with any antibody and serves as a true platform technology with the potential to fundamentally change the antibody treatment landscape. Antibodies are currently being used for numerous therapeutic indications and many more are in clinical development. The increased use of antibodies, largely for the treatment of a broad range of cancers and inflammatory diseases, has greatly improved the standard of care for patients. RenBio’s MYO technology will further build upon these advancements and revolutionize the treatment landscape.  

Antibody therapeutics have revolutionized
disease treatment

Our bodies normally produce antibodies in response to infections. They are made by specialized cells within our immune system and can target nearly any foreign invaders, such as viruses and bacteria. Antibodies are akin to multipurpose tools, and when they bind their target, they can initiate processes that are not only important for fighting infections, they can be used to defend against other diseases as well, such as cancer and arthritis. The recognition that antibodies are useful for treatment of a wide variety of diseases has led to a huge expansion in the development and use of these very special proteins.

But the method of delivery to patients is in need of innovation

In order to manufacture antibodies, they must be produced in living cells cultured in a laboratory, which requires large, specialized facilities. And because the level of antibodies in the body declines over time after they are administered, they must be frequently dosed to maintain levels adequate for clinical effectiveness.

RenBio is revolutionizing
antibody delivery

Our MYO (Make Your Own) technology is built to overcome the current manufacturing and delivery challenges of standard therapies in order to revolutionize the state of antibody therapeutics by empowering patients to produce their own medicines.  

In doing so, we are creating radically new antibody therapies that are longer lasting than the current treatment paradigms. Our bodies already know how to produce antibodies, so why not provide patients with the DNA blueprint for therapeutic antibodies instead of the manufactured protein? 

MYO administration is easy

Antibody-encoding DNA molecules are injected into a patient’s muscle, then short electric pulses are applied to the muscle, allowing the muscle cells to internalize the DNA.

MYO technology is simple

Once inside the cell, the cell’s protein production machinery takes over; muscle cells begin synthesizing and secreting antibody molecules. The antibodies can then readily access the bloodstream through the abundant small blood vessels in muscle tissue, and from there travel to other parts of the body to perform their disease-fighting functions. 

MYO technology requires fewer treatments

And because the antibody DNA is stable in muscle cells for several months, antibodies are continually produced during this period, resulting in fewer treatments than with traditional antibody delivery.

MYO administration is easy

Antibody-encoding DNA molecules are injected into a patient’s muscle, then short electric pulses are applied to the muscle, allowing the muscle cells to internalize the DNA.  

MYO technology is simple

Once inside the cell, the cell’s protein production machinery takes over; muscle cells begin synthesizing and secreting antibody molecules. The antibodies can then readily access the bloodstream through the abundant small blood vessels in muscle tissue, and from there travel to other parts of the body to perform their disease-fighting functions. 

MYO technology requires fewer treatments

And because the antibody-encoding DNA is stable in muscle cells for several months, antibodies are continually produced during this period, resulting in fewer treatments than with traditional antibody delivery.